Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Chronic Subdural Hematomas
NCT02568124Phase 3Unknown
- Sponsor
- Centre de recherche du CHUS
- Start
- Nov 2015
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tranexamic acid in chronic subdural hematoma (CSDH), sponsored by Centre de recherche du CHUS. Primary endpoint: Rate of CSDH resolution without intervening unplanned surgical procedure at 20 weeks. Status: unknown.
02
Drugs
tranexamic acid
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT02568124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568124.